Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Lilly’s RET Inhibitor, Pfizer’s Oral JAK Drug Make Japan Debut
Eli Lilly launched its RET kinase inhibitor Retevmo (selpercatinib) in Japan on December 13 for the treatment of RET fusion-positive unresectable, advanced/relapsed non-small cell lung cancer (NSCLC). Retevmo is the world’s first selective, small-molecule RET kinase inhibitor approved for the…
To read the full story
Related Article
- November Listing OK’ed for Cibinqo, Retevmo, Padcev and More
November 17, 2021
- Japan Approves Padcev, Entresto’s Hypertension Use, Lilly’s RET Inhibitor and More
September 28, 2021
BUSINESS
- Eylea Biosimilar Shipment Restrictions to Be Lifted on June 5
May 27, 2026
- Bayer’s Low-Dose MRI Contrast Agent Ambelvist Debuts in Japan
May 27, 2026
- Eisai Eyes 1 Trillion yen in FY2028 Sales under 3-Year Plan
May 26, 2026
- Nippon Kayaku to Take Over AstraZeneca’s Zoladex in Japan
May 26, 2026
- Jardiance Triumphs in Six Promotion Channels in April: Intage
May 26, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…